Considering the conflicting results available in the literature, the use of GFAP and UCHL-1 in clinical practice for MS patients is not anticipated at present, given the uncertain correlation between serum and CSF values, as well as the non-standardized sampling times and techniques. Here, GFAP is linked to myeloid sarcoma.